Ramatroban
Chemical compound / From Wikipedia, the free encyclopedia
Ramatroban (INN) (also known as BAY u3405)[1] is a thromboxane receptor antagonist.[2]
Clinical data | |
---|---|
Trade names | Baynas |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral (tablets) |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.159.668 |
Chemical and physical data | |
Formula | C21H21FN2O4S |
Molar mass | 416.47 g·mol−1 |
3D model (JSmol) | |
| |
|
It is also a DP2 receptor antagonist.[3]
It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]
It has been suggested that ramatroban, by modulating DP2 receptor, can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced by SARS-Cov-2.[citation needed] Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of COVID-19 disease, although no clinical trial has yet been conducted.[6]
Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.